CRISPR Therapeutics, Capsida Collaborate To Develop Gene-Edited Therapies For Neurological Diseases

  • CRISPR Therapeutics CRSP has signed a deal with Capsida Biotherapeutics, a gene therapy player specializing in AAV engineering, to carve out a delivery mechanism for the company’s gene-editing technology in familial amyotrophic lateral sclerosis (ALS) and rare neurodegenerative disorder Friedreich’s ataxia.
  • As part of the agreement, Capsida will pick up R&D responsibilities for the ALS program and chip away at capsid design for both programs. Meanwhile, CRISPR will manage R&D for the FA program and develop gene-editing candidates for both.
  • Both companies will hold options to co-development and -commercialization rights for the program which the partner company leads.
  • The financial terms of the deal were not disclosed.
  • If one of the partners opts, the two firms would share R&D and commercialization costs and profits on that program.
  • Capsida, with its experience in AAV production, will handle clinical and commercial manufacturing, if it reaches that point.
  • Price Action: CRSP shares are trading up 0.57% at $129.50 in the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsGeneralBriefsgene therapyNeurological Disorders
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!